Eaton Vance Management Bei Gene, Ltd. Transaction History

Eaton Vance Management

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$121.11 - $216.05 $253,241 - $451,760	2,091 New	2,091 $338,000
Q1 2022 May 16, 2022	SELL	$146.52 - $269.56 $293 - $539	-2 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$248.56 - $389.34 $497 - $778	2 New	2 $1,000
Q3 2021 Nov 15, 2021	SELL	$249.6 - $403.14 $196,934 - $318,077	-789 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$292.75 - $367.01 $67,039 - $84,045	229 Added 40.89%	789 $270,000
Q1 2021 May 17, 2021	BUY	$260.64 - $382.12 $145,958 - $213,987	560 New	560 $194,000

253

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $22.7B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Eaton Vance Management, based on Form 13F filings with the SEC.

Stay updated on Eaton Vance Management with notifications on news.